Genocea Biosciences Inc. (NASDAQ:GNCA) has earned an average rating of “Buy” from the five analysts that are currently covering the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.25.

A number of equities research analysts have recently issued reports on the stock. FBR & Co reissued an “outperform” rating and issued a $17.00 price target on shares of Genocea Biosciences in a report on Monday, November 14th. Zacks Investment Research raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, November 3rd. Finally, Piper Jaffray Cos. lowered their price target on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, September 29th.

TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of United States and international copyright and trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/27/genocea-biosciences-inc-gnca-given-average-rating-of-buy-by-brokerages.html.

Large investors have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in shares of Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock worth $177,000 after buying an additional 6,763 shares in the last quarter. Northpointe Capital LLC increased its stake in shares of Genocea Biosciences by 90.2% in the third quarter. Northpointe Capital LLC now owns 1,438,286 shares of the company’s stock worth $7,364,000 after buying an additional 682,269 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Genocea Biosciences during the second quarter worth $334,000. Alpine Partners VI LLC bought a new stake in shares of Genocea Biosciences during the second quarter worth $120,000. Finally, TFS Capital LLC bought a new stake in shares of Genocea Biosciences during the second quarter worth $133,000. 58.67% of the stock is currently owned by institutional investors and hedge funds.

Shares of Genocea Biosciences (NASDAQ:GNCA) opened at 4.32 on Tuesday. The firm’s 50-day moving average is $3.95 and its 200-day moving average is $4.43. The company’s market capitalization is $122.60 million. Genocea Biosciences has a 12-month low of $2.56 and a 12-month high of $8.07.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.01. Genocea Biosciences had a negative return on equity of 57.92% and a negative net margin of 5,121.17%. On average, equities analysts predict that Genocea Biosciences will post ($1.64) EPS for the current year.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

5 Day Chart for NASDAQ:GNCA

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.